formation. Among the automation platforms that contribute to QIAGEN’s business: QIAsymphony is a modular system that has launched integrated workflow consolidation and laboratory automation, making workflows more efficient and helping to disseminate standardized, clinically proven molecular diagnostics. The company’s fully integrated QIAsymphony RGQ, launched in 2010, includes three modules - QIAsymphony SP for sample preparation, QIAsymphony AS for assay setup, and its real-time PCR platform Rotor-Gene Q. EZ1 Advanced XL performs automated nucleic acid purification for a range of sample types relevant for molecular diagnostics, human identity testing, forensics, biomedical research, and gene expression analysis. QIAcube is a sample processing instrument that incorporates novel and proprietary technologies allowing users to fully automate the use of all QIAGEN technologies originally designed for manual processing of samples. QIAcube HT enables automated mid- to high-throughput nucleic acid purification in 96-well format using silica membrane technology. Users can purify DNA, RNA, and miRNA from any type of sample, including cells, tissues, and food material, as well as from bacteria and viruses in animal samples. Rotor-Gene Q, the rotary real-time PCR cycler system, uses real-time PCR reactions to make sequences of DNA and RNA visible through amplification and quantifiable. It is an integral component of the QIAsymphony RGQ system. PyroMark is a high-resolution detection platform with Pyrosequencing technology that enables real-time analysis and quantification of genetic mutations and DNA methylation patterns. QIAgility is a compact benchtop instrument that enables rapid, high-precision PCR setup. QIAxcel replaces traditional slab-gel analysis, eliminating time-consuming nucleic acid separation methods in low- to high-throughput laboratories. ESEQuant Tube Scanners enable Point of Need testing in healthcare and other applications. These portable, battery-operated optical measurement devices permit low-throughput molecular testing in physician practices, emergency rooms, remote areas, and other settings with limited or delayed access to laboratory infrastructure. Customers The company sells to four major customer classes: Molecular Diagnostics comprising healthcare providers engaged in patient care including Prevention, Profiling of diseases, Personalized Healthcare and Point of Need testing; Applied Testing comprising government or industry customers using molecular technologies in fields, such as forensics, veterinary diagnostics and food safety testing; Pharma comprising pharmaceutical and biotechnology companies using molecular testing to support drug discovery, translational medicine and clinical development efforts; Academia comprising researchers exploring the secrets of life, such as disease mechanisms and pathways, in some cases translating findings into drug targets or other products; Intellectual Property As of December 31, 2014, the company owned 273 issued patents in the United States, 175 issued patents in Germany and 1,037 issued patents in other major industrialized countries. The company had 935 pending patent applications. Regulations Other Fraud and Abuse Laws The company must comply with a variety of other laws, such as laws prohibiting false claims for reimbursement under Medicare and Medicaid, all of which can also be triggered by violations of federal anti-kickback laws; the Health Insurance Portability and Accounting Act of 1996, which makes it a federal crime to commit healthcare fraud and make false statements; and the Federal Trade Commission Act and similar laws regulating advertisement and consumer protections. Competition The company’s competitors include Promega Corp.; EMD Millipore or Merck Millipore; Macherey-Nagel GmbH; Thermo Fisher; Promega Corp.; Sigma-Aldrich Corp.; Roche Diagnostics; Abbott; Siemens; Cepheid; and Hologic. History QIAGEN N.V. was founded in 1986.
qiagen n.v. (QGEN:NASDAQ GS)
Venlo, 5911 KJ
Phone: 31 77 320 8400
Fax: 31 77 320 8409www.qiagen.com
|Bio-Reference Laboratories Inc||$33.35 USD||-0.41|
|Myriad Genetics Inc||$34.60 USD||+0.13|
|PerkinElmer Inc||$53.39 USD||0.00|
|View Industry Companies|
Sponsored Financial Commentaries
To contact QIAGEN N.V., please visit www.qiagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.